{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red80\green80\blue80;
\red37\green37\blue37;
\red21\green137\blue21;
\red119\green119\blue119;
\red204\green204\blue204;
\red255\green255\blue102;
\red14\green86\blue140;
\red246\green246\blue246;
\red247\green247\blue247;
\red61\green61\blue61;
\red33\green33\blue33;
\red238\green238\blue238;
\red20\green93\blue164;
\red107\green107\blue106;
\red249\green250\blue251;
\red228\green231\blue232;
\red51\green51\blue51;
\red187\green187\blue187;
\red254\green254\blue0;
\red56\green124\blue43;
\red151\green151\blue151;
\red233\green233\blue233;
\red181\green79\blue104;
\red112\green112\blue112;
\red0\green114\blue54;
\red106\green144\blue39;
\red239\green122\blue2;
\red232\green233\blue232;
\red249\green249\blue249;
\red204\green255\blue255;
\red223\green223\blue223;
\red239\green239\blue239;
\red183\green242\blue206;
\red255\green255\blue174;
\red214\green9\blue9;
\red255\green248\blue96;
\red240\green240\blue240;
\red105\green105\blue105;
\red227\green227\blue227;
\red33\green74\blue204;
\red188\green41\blue30;
\red190\green237\blue228;
\red214\green214\blue214;
\red242\green242\blue242;
\red236\green236\blue236;
\red255\green255\blue198;
\red172\green172\blue172;
\red9\green56\blue84;
\red203\green203\blue203;
\red245\green245\blue245;
\red229\green243\blue255;
\red179\green218\blue255;
\red127\green127\blue127;
\red71\green120\blue194;
\red255\green210\blue183;
\red120\green162\blue47;
\red251\green252\blue255;
\red102\green0\blue102;
\red182\green231\blue243;
\red185\green185\blue185;
\red218\green218\blue218;
\red190\green190\blue252;
\red240\green248\blue255;
\red118\green118\blue118;
\red221\green195\blue236;
\red61\green61\blue60;
\red89\green89\blue89;
\red86\green86\blue86;
\red16\green58\blue89;
\red255\green204\blue153;
\red23\green94\blue146;
\red149\green246\blue220;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 sans-serif;}{
\f4 georgia;}{
\f5 serif;}{
\f6 Source Sans Pro;}{
\f7 Helvetica;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj \paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Boehringer Ingelheim Pharmaceuticals Inc. v. Mylan..., 803 Fed.Appx. 397...
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 89504e470d0a1a0a0000000d494844520000004e0000000a08030000002dbd985500000300504c5445f8a969f6913ff68931fff9f5f69241f5852af68d38fcddc4f58326fac294f8a868fac193fcdabefab985fcdfc7fef5eef58022f8a35efef6effde5d2fac092fffaf6f9ac6ffffcfafde8d7fef7f1f9b279f6862cf8aa6af79e56f79c53f58327fef1e7fde3cefeeee2f9b076f79a4efef8f4f58123f58224f9ae72feefe4f58021f9ae71fac295fffaf7fcdabffef7f2f9af73f9b177f8ac6ef9b47cf8a15bf6872ef79648fef5edf9b278fcd9bdf9b782f9b57efbc89ffde3cffffefdf6872df8aa6bfcd6b8fac59af9b781fabc8bfffbf8fac091fac396fbceaaf8a461f68e39f6882ffabe8dfabf8ff9b884f79c52fdeadbfeede0f68c36f89f58fcdcc3fde0c9fef0e5fef3eaf68f3cfbcaa2f8a867f9b37afaba87f68b35fde7d6fabf90fffcfbfaba86fde7d5f6903efffdfcfef4ecf68f3bfde1cafcdfc6fbd1affbcea9fcd6b7f68a33f79444fbcba5f58429fcdec6f9af74f8a25df58428f7a461fef4edfdede0fde6d4fde7d4f9b680fbc69cfbc8a0f9b37bfac9a1f69240f79d54fcd4b4f9b883f68e3afef8f3fdebddfde2cbf7984cf8a35ff6882efef3ebf9bd8cfcd4b5feecdef8a562fde6d3fef9f4fcdbc1f9bc8afcd8bcf8ab6dfef8f2fcd7b9fffbf7feefe3f79546f8aa69f79f57fde1cbfcd3b3fcd2b1f8a25cfcd3b2fde2ccfac599fac397f9b379fcd8bbfbd2b0fef2e9fcd5b6fac79ef8a664f8a460f68a32fac090fffbf9fef2e8f8ab6cfde4d0f7994df6903df79749fffefcf79e55f8a766f8a059f68830f7974afde2cdfbcca6fabd8cf57f20ffffff000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000c5baaa8e000000bf74524e53ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff00456e8439000002804944415478da63dcc70001fef2931866b0be0cd2085114e5ff7ef72a0357d0a3a31cc2129ebb9f492a3e4b6eb8cb20913bb5c808a2f849bf610c438bf99a9917cf2a18092c7bf1a30a6a0a13946658f6af92e15352e52386af5d677ee5ff61618c5ca7c6b58921d6ecc47383e56a52b3181955bf2e3e01513b49bae7260383be8b048376a2e34786a3853761a6b0c018892b57313c48fa38834195c1cf94c16a3a03c3edad7c5f163030a8672bcc3afcf4251343639ef3ae2cb05afe384e9390352a0c320cbdf71f19b43d6690c7302e84e11383d28bff67bcba9a6e2831acd9c6e0d990fe70b74ae7d2a90c0cbbc36fbaef6660b80f55ba68e9d2d5a9ae0cdd2f341878be8b9c64f8cb701d660a733c9451af78704effa1c6b3536708cf2c9ffde7c78fcb9b16497b8acf3e3721061812bfde8433302c8d5a190152ca93f7d26df6796bff83310dbfe504de7f7ff9ec621c7ad8ade964d5f0f8162da4257e9da18c39434955602283a37fdaefde9cb30c686005c3a4c9a6d792186c6b665d8e54f97ae7c5badd189e65307c22395565fbc43fcc010cad5b3ba781c5363184af0bfa8530481844b84e65b87efde6bcb50c67d9dc36d4f6bf7aa6e4015700771dc3fd57751f183c97ecfe7f04c8b17e9f9fdfceb0e334c3ca37c16940feb644b09ad7e1aee90cdaaa9f1ca31ef6bd6478e2b43ba29f615fc7cf550c1861c720c2699619c930d362d55a060ff68e592f7d4eacd82df9eb3bd7bd387986ff73182d18183686ba2ff9f76ec59f909c2e83a8499dbbaaa404ecf8199cb8051e79627ad6fa4799360383602cd0bdcbdeb2fc6158debec577daf1a9076ba51818e679bf05aaf85cfdeb0f8383c1ec0973801cee342386c537cdf218fecf4b70801b0200f61ff095f54de6170000000049454e44ae426082}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_67}{\*\bkmkend co_document_67}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart Ia75a2d8067e811eab47fc33bf795b230_Target}{\*\bkmkend Ia75a2d8067e811eab47fc33bf795b230_Target}
\par 
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
803 Fed.Appx. 397
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This case was not selected for publication in West\rquote s Federal Reporter.
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
See Fed. Rule of Appellate Procedure 32.1 generally governing citation of judicial decisions issued on or after Jan. 1, 2007. See also U.S.Ct. of App. Fed. Cir. Rule 32.1.
\par 
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States Court of Appeals, Federal Circuit.
\par 
}
}
}
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
BOEHRINGER INGELHEIM PHARMACEUTICALS INC., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG, Plaintiffs-Appellants
\par 
}
}
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf20 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
MYLAN PHARMACEUTICALS INC., Mylan Inc., Mylan Laboratories Limited, Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Defendants-Appellees
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2019-1172
\par 
}
}
}
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Decided: March 16, 2020
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf29 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_67}{\*\bkmkend co_synopsis_67}
{\b1 \cf29 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Owner of patents related to treatment of type 2 diabetes mellitus with DPP-IV inhibitors brought infringement action. Competitors moved for judgment on the pleadings related to one patent. The United States District Court for the District of New Jersey, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0196120501&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Peter G. Sheridan
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040501436&pubNum=0000999&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2016 WL 7177704
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, granted motion, finding that claims were patent ineligible. Following bench trial, the District Court determined other claims were invalid as obvious. Patent owner appealed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court of Appeals, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0368246101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moore
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, Circuit Judge, held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims in patent related to treatment and/or prevention of metabolic diseases such as type 2 diabetes mellitus with DPP-IV inhibitors such as linagliptin were patent eligible, and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims related to treatment of type 2 diabetes mellitus with linagliptin in 2.5 or 5 mg doses were invalid as obvious.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Affirmed in part, reversed in part, and remanded.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Appeal from the United States District Court for the District of New Jersey in Nos. 3:15-cv-05982-PGS-TJB, 3:16-cv-00851-PGS-TJB, 3:16-cv-00852-PGS-TJB, 3:16-cv-01727-PGS-TJB, 3:16-cv-02394-PGS-TJB, Senior Judge 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0196120501&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Peter G. Sheridan
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b1 \cf29 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_67}{\*\bkmkend co_attorneysAndLawFirms_67}
{\b1 \cf29 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0251979601&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Leora Ben-Ami
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Kirkland & Ellis LLP, New York, NY, argued for plaintiffs-appellants. Also represented by Mira Atanassova Mulvaney, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0366978401&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jeanna Wacker
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0154933501&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Liza M. Walsh
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Walsh Pizzi O\rquote Reilly Falanga LLP, Newark, NJ.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Deepro Mukerjee, Katten Muchin Rosenman LLP, New York, NY, argued for all defendants-appellees. Defendants-appellees Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0438083601&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lance Soderstrom
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0465589901&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Joseph Janusz
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Charlotte, NC; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0241924901&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Howard Robert Rubin
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0509881601&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rajesh Ram Srinivasan
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0489555099&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Eric Thomas Werlinger
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Washington, DC; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0438040301&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christopher L. McArdle
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0154028101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Thomas J. Parker
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Alston & Bird LLP, New York, NY.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0197230901&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jeffrey Stephen Ward
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Green, Griffith & Borg-Breen LLP, Middleton, WI, for defendants-appellees Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0405517201&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Wendy M. Ward
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0475931201&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Paige Stradley
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Merchant & Gould P.C., Minneapolis, MN.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Before 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0127930301&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dyk
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0368246101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moore
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0211865201&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hughes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Circuit Judges.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf29 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_67}{\*\bkmkend co_opinion_67}
{\b1 \cf29 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Opinion
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I95969f62bb2211ea8c5edf85caaea}{\*\bkmkend co_anchor_I95969f62bb2211ea8c5edf85caaea}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0368246101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moore
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, Circuit Judge.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I95a5e1a2bb2211ea8c5edf85caaea}{\*\bkmkend co_anchor_I95a5e1a2bb2211ea8c5edf85caaea}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_398_67}{\*\bkmkend co_pp_sp_6538_398_67}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*398
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Appellants Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, and Boehringer Ingelheim Pharma GmbH & Co. KG (collectively, Boehringer) sued Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories, Ltd., Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. (collectively, Appellees) for infringement of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent Nos. 8,853,156
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037527063&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I471a0b70833611e5b7fb83303a8f4719&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
9,173,859
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032915083&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=Icbec9100af8011e3a70c8846ed0e9159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
8,673,927
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which relate to the treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with DPP-IV inhibitors such as linagliptin. Appellees moved for partial judgment on the pleadings under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 alleging that claims 10-17, 24 and 25 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed to ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court granted Appellees\u8217\'3f motion, holding the claims patent ineligible under the two-step framework of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_780_217&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_217" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corporation Pty. Ltd. v. CLS Bank International
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 573 U.S. 208, 217, 134 S.Ct. 2347, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A bench trial ensued on the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037527063&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I471a0b70833611e5b7fb83303a8f4719&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f859
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032915083&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=Icbec9100af8011e3a70c8846ed0e9159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f927 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court held that claims 1, 14, 15, 20, and 21 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037527063&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I471a0b70833611e5b7fb83303a8f4719&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f859 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claims 7, 9, 15, 17, 19, 25, and 26 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032915083&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=Icbec9100af8011e3a70c8846ed0e9159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f927 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are invalid for obviousness-type double patenting in light of the claims of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027698545&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I91963cb09f5e11e1b737ac343f7180c7&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 8,178,541
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and invalid as obvious in view of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004499703&pubNum=0006769&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I7dcff727abd311d8a0b485fe1f21ef34&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent Application Publication No. 2004/0097510
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Boehringer appealed. We have jurisdiction under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1295&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_7b9b000044381" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1295(a)(1)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the reasons discussed below, we reverse the district court\u8217\'3fs judgment that claims 10\u8211\'3f17, 24 and 25 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed to ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and remand for further proceedings. We affirm the district court\u8217\'3fs judgment that the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037527063&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I471a0b70833611e5b7fb83303a8f4719&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f859
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032915083&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=Icbec9100af8011e3a70c8846ed0e9159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f927 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are invalid for obviousness and obviousness-type double patenting.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I95a879b1bb2211ea8c5edf85caaea}{\*\bkmkend co_anchor_I95a879b1bb2211ea8c5edf85caaea}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Discussion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
I
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf25 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12050573550_67}{\*\bkmkend co_anchor_B12050573550_67}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court granted Appellees\u8217\'3f motion for judgment on the pleadings under 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_399_67}{\*\bkmkend co_pp_sp_6538_399_67}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*399
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 holding claims 10\u8211\'3f17, 24 and 25 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court held that the claims are directed to an \u8220\'3fabstract idea,\u8221\'3f namely \u8220\'3fthe act of administering the DPP-IV inhibitor to the targeted patient population.\u8221\'3f J.A. 108\u8211\'3f09. The district court further determined that the claims fail to recite an inventive concept.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012050573550_ID0EEPAE_67}{\*\bkmkend co_fnRef_B00012050573550_ID0EEPAE_67}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012050573550_67" }{\fldrslt 
{\super \b0 \cf25 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We review a district court\u8217\'3fs 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 dismissal for judgment on the pleadings under the law of the regional circuit. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040226409&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1293" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Amdocs (Isr.) Ltd. v. Openet Telecom, Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 841 F.3d 1288, 1293 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Third Circuit reviews a grant of judgment on the pleadings de novo. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037447858&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_764&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_764" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Hanover Ins. Co. v. Urban Outfitters, Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 806 F.3d 761, 764 (3d Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In doing so, the Third Circuit views \u8220\'3fthe facts presented in the pleadings and the inferences to be drawn therefrom in the light most favorable to the nonmoving party.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037447858&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotations omitted). Eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a question of law based on underlying facts that, ultimately, we review de novo. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2045179669&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1166&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1166" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
SAP Am., Inc. v. InvestPic, LLC
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 898 F.3d 1161, 1166 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In determining patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fwe first determine whether the claims at issue are \u8216\'3fdirected to\u8217\'3f a patent ineligible concept.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047780027&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1342&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1342" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Natural Alternatives Int\u8217\'3fl, Inc. v. Creative Compounds, LLC
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 918 F.3d 1338, 1342 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_780_218&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_218" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. at 218, 134 S.Ct. 2347
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). \u8220\'3fAs the Supreme Court has cautioned, we must be careful in this analysis as \u8216\'3ftoo broad an interpretation of this exclusionary principle could eviscerate patent law. For all inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047780027&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1342&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1342" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1342
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_780_71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_71" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 71, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047780027&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1345&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1345" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1345
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe fact that the human body responds to the treatment through biochemical processes does not convert the claim into an ineligible one.\u8221\'3f). We conclude claims 10\u8211\'3f17, 24 and 25 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed to patent eligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 relates to the treatment and/or prevention of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with DPP-IV inhibitors such as linagliptin \u8220\'3fin patients for whom normal 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy is not appropriate.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1:5\u8211\'3f11. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Type 2 diabetes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 may be associated with complications such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib89aa8ef475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1:17\u8211\'3f21. Because 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is largely eliminated by the kidneys, \u8220\'3fit is contraindicated in patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic7953171475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1:62\u8211\'3f65. The specification indicates that \u8220\'3fit has now surprisingly been found that DPP-4 inhibitors as defined herein have surprising and particularly advantageous properties, which make them particularly suitable for treating and/or preventing ... 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, particularly 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic21f078b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
diabetes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ... in patients for whom 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy is inappropriate due to intolerability or contraindication against 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
....\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_400_67}{\*\bkmkend co_pp_sp_6538_400_67}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*400
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 9:30\u8211\'3f39. It further explains, for example, that \u8220\'3f[t]he DPP-4 inhibitor is substantially or mainly excreted via the liver....\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 13:45\u8211\'3f46.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claims 1 and 10 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recite:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. A method of treating and/or preventing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a patient for whom 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy is inappropriate due to at least one contraindication against 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 comprising orally administering to the patient a DPP-IV inhibitor wherein the contraindication is selected from the group consisting of: 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic7953171475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or renal dysfunction, unstable or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib3ef21e5475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
acute congestive heart failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, acute or chronic 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibf4385e8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic acidosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and hereditary 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib81069fe475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
galactose intolerance
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
10. The method according to claim 1 wherein the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and wherein the contraindication is 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic7953171475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 or renal dysfunction, and wherein said DPP-4 inhibitor is used for said patient in the same dose as for a patient with normal renal function.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Boehringer argues that the claims are directed to a \u8220\'3fmethod of treating a specific disease ( [
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
] ) for specific patients (with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) using a specific compound (linagliptin) at specific doses (same dose in patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as in patients with normal renal function) to achieve a specific outcome.\u8221\'3f Appellants\u8217\'3f Br. 38. Appellees argue that the claims are directed to the natural law that \u8220\'3fcertain DPP-IV inhibitors (including linagliptin) are metabolized by the liver rather than the kidney.\u8221\'3f Appellees\u8217\'3f Br. 38; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 43.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We hold that, consistent with this court\u8217\'3fs decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Ltd.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d 1117 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the claims are directed to a particular method of treatment under step one and are therefore patent eligible. The claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 involved a method of treating patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that first required performing a genetic test to determine if a patient was a CYP2D6 poor metabolizer. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1121&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1121" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1121
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Based on the results of that test, a particular dose of iloperidone was selected and internally administered. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As a result, the risk of QTc prolongation, a dangerous side effect, was decreased. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1121&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1121" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1121 & n.2
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We held that the claims were not directed to a natural relationship between iloperidone, CYP2D6 metabolism, and QTc prolongation. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1134&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1134" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1134
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While we acknowledged that the inventors had recognized the underlying relationships, we explained that those were not what was claimed. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1135
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Instead, the claims were directed to a patent-eligible method of using iloperidone to treat 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fa specific method of treatment for specific patients using a specific compound at specific doses to achieve a specific outcome.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1136&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1136" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1136
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_780_87&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_87" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 87, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (distinguishing the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claim from \u8220\'3fa typical patent on a new drug or a new way of using an existing drug,\u8221\'3f because the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claim did not \u8220\'3fconfine [its] reach to particular applications\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the natural laws relied upon).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are likewise directed to a method of treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 using a DPP-IV inhibitor, such as linagliptin.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022050573550_ID0EBLAG_67}{\*\bkmkend co_fnRef_B00022050573550_ID0EBLAG_67}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022050573550_67" }{\fldrslt 
{\super \b0 \cf25 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 That \u8220\'3fcertain DPP-IV inhibitors (including linagliptin) are metabolized by the liver rather than the kidney,\u8221\'3f Appellees\u8217\'3f Br. 38, \u8220\'3fdoes not make the claim \u8216\'3fdirected to\u8217\'3f that natural ability.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1049&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1049" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litigation Mgmt. Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042, 1049 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (stating that the \u8220\'3fnatural ability 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_401_67}{\*\bkmkend co_pp_sp_6538_401_67}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*401
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the subject matter to 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
undergo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the process does not make the claim \u8216\'3fdirected to\u8217\'3f that natural ability\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Because we hold that the claims are directed to a method of treatment at step one, we conclude the claims are patent eligible and need not reach step two. We do not, of course, at this stage address the issues of obviousness and obviousness-type double patenting with respect to these claims. Accordingly, we reverse the district court\u8217\'3fs grant of judgment on the pleadings and remand to the district court for further proceedings.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I95b34f21bb2211ea8c5edf85caaea}{\*\bkmkend co_anchor_I95b34f21bb2211ea8c5edf85caaea}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
II
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf25 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22050573550_67}{\*\bkmkend co_anchor_B22050573550_67}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court held claims 1, 14, 15, 20, and 21 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037527063&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I471a0b70833611e5b7fb83303a8f4719&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f859 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claims 7, 9, 15, 17, 19, 25, and 26 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032915083&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=Icbec9100af8011e3a70c8846ed0e9159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f927 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (collectively, the claims at issue) invalid for obviousness-type double patenting and invalid as obvious in view of the prior art. On appeal from a bench trial, we review a district court\u8217\'3fs conclusions of law de novo and its findings of fact for clear error. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033239225&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1358&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1358" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Braintree Labs., Inc. v. Novel Labs., Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 749 F.3d 1349, 1358 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fA factual finding is clearly erroneous when, despite some supporting evidence, we are left with a definite and firm conviction that the district court was in error.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032909107&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1186&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1186" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alcon Research Ltd. v. Barr Labs., Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 745 F.3d 1180, 1186 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010230679&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1289&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1289" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alza Corp. v. Mylan Labs., Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 464 F.3d 1286, 1289 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). \u8220\'3fWhere there are two permissible views of the evidence, the factfinder\u8217\'3fs choice between them cannot be clearly erroneous.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1985114055&pubNum=0000780&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_780_574&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_574" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Anderson v. City of Bessemer City
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 470 U.S. 564, 574, 105 S.Ct. 1504, 84 L.Ed.2d 518 (1985)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1949119312&pubNum=0000780&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_780_342&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_342" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
United States v. Yellow Cab Co.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 338 U.S. 338, 342, 70 S.Ct. 177, 94 L.Ed. 150 (1949)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Obviousness is a question of law based on underlying facts, including the scope and content of the prior art. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028393489&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1360&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1360" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Kinetic Concepts, Inc. v. Smith & Nephew, Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 688 F.3d 1342, 1360 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fAs with statutory obviousness under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf25 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, obviousness-type double patenting is an issue of law premised on underlying factual inquiries.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028474585&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Eli Lilly and Co. v. Teva Parenteral Meds., Inc.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 689 F.3d 1368, 1376 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The claims at issue relate to the treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with linagliptin in 2.5 or 5 mg doses. As to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037527063&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I471a0b70833611e5b7fb83303a8f4719&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f859 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, claim 14 is illustrative:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
14. An oral tablet formulation comprising 1-[ (4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in an amount of 2.5 mg or 5 mg optionally in combination with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, and a pharmaceutically acceptable carrier or diluent.
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032915083&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=Icbec9100af8011e3a70c8846ed0e9159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f927 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, claim 7, which depends from claim 1, is illustrative:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. A method of treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type II diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 comprising administering to a patient in need thereof a pharmaceutically effective oral amount of 1-[ (4-methyl-quinazolin-2-yl)-methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and a pharmaceutically effective amount of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which is from 300 mg to 1000 mg once or twice a day, or delayed-release 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 in a dose of 500 mg to 1000 mg once or twice a day or 500 mg to 2000 mg once a day.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
7. The method according to claim 1, wherein the 1-[ (4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is administered in an oral dosage of 2.5 mg or 5 mg.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court held that the claims at issue are invalid for obviousness-type double patenting in light of the claims of Boehringer\u8217\'3fs earlier-expiring 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027698545&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I91963cb09f5e11e1b737ac343f7180c7&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f541 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. It also held that the claims would have been obvious in light of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004499703&pubNum=0006769&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I7dcff727abd311d8a0b485fe1f21ef34&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f510 publication
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (the priority application with the same 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_402_67}{\*\bkmkend co_pp_sp_6538_402_67}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*402
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 specification as the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027698545&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I91963cb09f5e11e1b737ac343f7180c7&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f541 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Boehringer argues that both of these conclusions depend on the district court\u8217\'3fs determination that the claimed dosages would have been obvious. The district court determined that because \u8220\'3fthe claimed invention\u8217\'3fs doses of linagliptin in 2.5 mg and 5 mg fall within the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004499703&pubNum=0006769&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I7dcff727abd311d8a0b485fe1f21ef34&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f510 publication
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[\u8217\'3f]s disclosed range of 1\u8211\'3f100 mg,\u8221\'3f there is a presumption of obviousness. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 164 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025531835&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&fi=co_pp_sp_506_1372&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1372" }{\fldrslt 
{\b0 \cf25 \f2 \i1 \fs20 
{\b0 \cf25 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Tyco Healthcare Grp. LP v. Mutual Pharm. Co.
}
}
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 642 F.3d 1370, 1372\u8211\'3f73 (Fed. Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The district court alternatively found that a person of ordinary skill in the art would have obtained the claimed dosages through routine experimentation. Because we conclude that the district court\u8217\'3fs alternative finding is not clearly erroneous, we need not decide whether the district court\u8217\'3fs presumption determination was correct.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In view of the evidence presented, the district court did not clearly err in determining that a skilled artisan would \u8220\'3fhave a reasonable expectation of arriving at the claimed 2.5 mg and 5 mg dosages\u8221\'3f through routine experimentation. J.A. 154; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 164. For example, Dr. Grass testified that dose ranging studies are \u8220\'3fconducted starting with a low dose, and sequentially moving through increasing doses.\u8221\'3f J.A. 147 (quoting J.A. 1037 at 720:6\u8211\'3f9, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 720:10\u8211\'3f721:10); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 1158 at 1060:2\u8211\'3f5 (Dr. Lam agreeing that \u8220\'3fa person of ordinary skill in the art would understand the general guidelines that were issued by the FDA would include ... dose-ranging studies\u8221\'3f); J.A. 1259 at 1356:7\u8211\'3f10 (Dr. Accili agreeing that dose-ranging studies are required for FDA approval). Dr. Grass further testified that linagliptin has a low IC50 value disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004499703&pubNum=0006769&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I7dcff727abd311d8a0b485fe1f21ef34&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f510 publication
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 indicating that it has a high potency. J.A. 1045 at 752:19\u8211\'3f753:6 (\u8220\'3fUsing the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004499703&pubNum=0006769&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I7dcff727abd311d8a0b485fe1f21ef34&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f510
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 which we spoke about earlier, one would recognize that linagliptin is disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004499703&pubNum=0006769&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I7dcff727abd311d8a0b485fe1f21ef34&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f510
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; it\u8217\'3fs a compound that\u8217\'3fs shown to have ... the lowest IC50 value or the greatest potency; there\u8217\'3fs a preferred dose range of 1 to 100 milligrams; and there\u8217\'3fs a preferred list of compounds in which linagliptin is a member; one would be guided through that information of looking at the lowest end of the dose range for the most potent compound....\u8221\'3f). Additionally, one of the inventors of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037527063&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I471a0b70833611e5b7fb83303a8f4719&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f859
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032915083&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=Icbec9100af8011e3a70c8846ed0e9159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f927 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dr. Dugi, testified that \u8220\'3f[r]egulators expect you to define the lowest maximum therapeutic dose,\u8221\'3f which may have the benefits of: (1) being a smaller, easier to swallow tablet; (2) being easier to formulate in combination pills; (3) having a lower risk of drug to drug interactions; and (4) reducing the risk of side effects. J.A. 1286 at 1464:11\u8211\'3f17; J.A. 1289 at 1476:4\u8211\'3f1477:16; J.A. 152\u8211\'3f53. Finally, we see no clear error in the district court\u8217\'3fs secondary consideration analysis.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, we affirm the district court\u8217\'3fs decision holding the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037527063&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=I471a0b70833611e5b7fb83303a8f4719&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f859
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032915083&pubNum=0004074&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=PA&docFamilyGuid=Icbec9100af8011e3a70c8846ed0e9159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f927 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 invalid for obviousness and obviousness-type double patenting.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I95b990b1bb2211ea8c5edf85caaea}{\*\bkmkend co_anchor_I95b990b1bb2211ea8c5edf85caaea}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Conclusion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
REVERSED-IN-PART, AFFIRMED-IN-PART, AND REMANDED
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I95b9ded1bb2211ea8c5edf85caaea}{\*\bkmkend co_anchor_I95b9ded1bb2211ea8c5edf85caaea}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Costs
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Each party shall bear its own costs.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf29 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_67}{\*\bkmkend co_allCitations_67}
{\b1 \cf29 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
803 Fed.Appx. 397
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012050573550_67}{\*\bkmkend co_footnote_B00012050573550_67}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012050573550_ID0EEPAE_67" }{\fldrslt 
{\super \b0 \cf25 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf25 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The district court determined that \u8220\'3fthe additional features recited in claim 1 do not amount to \u8216\'3fsignificantly more,\u8217\'3f which transform the abstract idea of administering the DPP-IV inhibitor to a patent eligible subject matter.\u8221\'3f J.A. 111. As to claim 10, it declared that the additional features are \u8220\'3fwell-understood, routine, and conventional features that do not transform the abstract idea recited in claim 1 into a patent eligible subject matter.\u8221\'3f J.A. 114. Similarly, \u8220\'3fthe additional features recited in claims 11\u8211\'3f17 do not add \u8216\'3fsignificantly more\u8217\'3f to the abstract idea of claim 1\u8221\'3f such that \u8220\'3fclaims 11\u8211\'3f17 do not render claim 1 patent eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf25 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf25 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf25 \f3 \i0 \fs18 \chcbpat2 
}\b0 \cf25 \f3 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.\u8221\'3f J.A. 115. Finally, as to claims 24 and 25, their additional features \u8220\'3fdo not add significantly more to the abstract idea of administering a DPP-IV inhibitor such that they transform the abstract idea into patent eligible subject matter.\u8221\'3f J.A. 116.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022050573550_67}{\*\bkmkend co_footnote_B00022050573550_67}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022050573550_ID0EBLAG_67" }{\fldrslt 
{\super \b0 \cf25 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf25 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
We recognize that the district court made its decision in 2016 without the benefit of our decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=Ia75a2d8067e811eab47fc33bf795b230&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf25 \f3 \i1 \fs18 
{\b0 \cf25 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Vanda
}
}\b0 \cf25 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and its progeny, which dictate the conclusion we reach today.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf22 \f3 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf22 \f3 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf22 \f3 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf22 \f3 \ri29 \i0 \fs19 \li29 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf22 \f3 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }